



**Washington State Health Care Authority
Prescription Drug Program**

626 8th Ave SE, Olympia, WA 98501 • 206-521-2029

<https://www.hca.wa.gov/about-hca/prescription-drug-program>

December 8, 2021

Dear Interested Party,

Based on recommendations by the Washington State Pharmacy and Therapeutics Committee, the Health Care Authority, Uniform Medical Plan (UMP), and the Department of Labor & Industries (L&I) have named the following drugs as preferred in their respective therapeutic classes on the Washington State Preferred Drug List (PDL), effective January 1, 2022:

MS Drugs reviewed 10/21/2020		Agency Coverage	
Ingredient Name	Label Name of Preferred Product	L&I	UMP
dimethyl fumarate	dimethyl fumarate capsule	No	Yes
	dimethyl fumarate starterpack	No	Yes
fingolimod HCL	Gilenya [®] capsule	No	Yes
glatiramer acetate	glatiramer acetate syringe	No	Yes
	Glatopa [®] syringe	No	Yes
interferon beta-1A	Avonex [®] kit	No	Yes
	Avonex Pen [®] kit	No	Yes
teriflunomide	Aubagio [®] tablet	No	Yes
The effect of this recommendation is to make Tecfidera [®] non-preferred and Aubagio [®] preferred on the WA PDL.			

Diabetes Drugs – DPP-4 reviewed 2/19/2020		Agency Coverage	
Ingredient Name	Label Name of Preferred Product	L&I	UMP
alogliptin benzoate	alogliptin tablet	Not participating	Yes
alogliptin/metformin HCL	alogliptin/metformin HCL tablet	Not participating	Yes
alogliptin/pioglitazone	alogliptin/pioglitazone tablet	Not participating	Yes
linagliptin	Tradjenta [®] tablet	Not participating	Yes
linagliptin + metformin	Jentaducto [®] tablet	Not participating	Yes
	Jentaducto XR [®] tablet	Not participating	Yes

The effect of this recommendation is no change to the WA PDL.

Diabetes Drugs – GLP-1 Agonist		Agency Coverage	
Ingredient Name	Label Name of Preferred Product	L&I	UMP
dulaglutide	Trulicity [®] pen	Not participating	Yes
exenatide	Byetta [®] solution	Not participating	Yes
	Byetta [®] pen	Not participating	Yes
liraglutide	Victoza [®] solution	Not participating	Yes
semaglutide	Ozempic [®] pen	Not participating	Yes
	Rybelsus [®] tablet	Not participating	Yes

The effect of this recommendation is to make Trulicity[®] preferred on the WA PDL.

Diabetes Drugs – SGLT2 Inhibitors		Agency Coverage	
Ingredient Name	Label Name of Preferred Product	L&I	UMP
dapagliflozin propanediol	Farxiga [®] tablet	Not participating	Yes

dapagliflozin/ metformin ER	Xigduo XR [®] tablet	Not participating	Yes
empagliflozin	Jardiance [®] tablet	Not participating	Yes
empagliflozin/ metformin HCL	Synjardy [®] tablet	Not participating	Yes
	Synjardy XR [®] tablet	Not participating	Yes
The effect of this recommendation is no change to the WA PDL.			


Targeted Immune Modulator (TIM) reviewed 4/21/2021		Agency Coverage	
Ingredient Name	Label Name of Preferred Product	L&I	UMP
adalimumab	Humira [®] kit	No	Yes
	Humira Pen [®] kit	No	Yes
	Humira Pediatric Crohns Disease Starter Pack [®] kit	No	Yes
	Humira Pen-Crohns Disease Starter [®] kit	No	Yes
	Humira Pen-Psoriasis Starter [®] kit	No	Yes
apremilast	Otezla [®] tablet	No	Yes
etanercept	Enbrel [®] kit	No	Yes
	Enbrel [®] solution	No	Yes
	Enbrel [®] syringe	No	Yes
	Enbrel Mini [®] solution	No	Yes
	Enbrel Sureclick [®] auto injector	No	Yes
	Enbrel Sureclick [®] solution	No	Yes
risankizumab	Skyrizi [®] pen	No	Yes
secukinumab	Cosentyx [®] solution	No	Yes
	Cosentyx [®] syringe	No	Yes
	Cosentyx Sensoready Pen [®] auto injector pen	No	Yes
tofacitinib citrate	Xeljanz [®] solution and tablet	No	Yes
	Xeljanz XR [®] tablet	No	Yes
ustekinumab	Stelara [®] solution	No	Yes
	Stelara [®] syringe	No	Yes
upadacitinib	Rinvoq [®] tablet	No	Yes
The effect of this recommendation is to make Skyrizi [®] , Rinvoq [®] , and Xeljanz [®] preferred on the WA PDL.			

Newer Anticoagulant Drugs reviewed 6/20/2018		Agency Coverage	
Ingredient Name	Label Name of Preferred Product	L&I	UMP
apixaban	Eliquis [®] tablet	No	Yes
dabigatran etexilate mesylate	Pradaxa [®] capsule	No	Yes
rivaroxaban	Xarelto [®] tablet	No	Yes
The effect of this recommendation is to make Xarelto [®] preferred on the WA PDL.			

Each agency will use the common PDL according to its benefit structure. You may view the current PDL on our [website](#).

If you have other questions or comments regarding this announcement, please contact Leta Evaskus at (206) 521-2029 or by email at leta.evaskus@hca.wa.gov.

Sincerely,



Donna Sullivan
Chief Pharmacy Officer
Clinical Quality and Care Transformation
Washington State Health Care Authority